surgical management of mammary tumour in canines
DESCRIPTION
TRANSCRIPT
![Page 1: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/1.jpg)
“SURGICAL MANAGEMENT OF MAMMARY TUMOUR IN CANINE”
Presented By –
Dr. Manzoor Ahmad bhat
m. v. sc. Scholar
Department of Veterinary Surgery and Radiology
![Page 2: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/2.jpg)
MAMMARY TUMOUR (MT)
Neoplasia which involve mammary gland Most common in bitches, rare in male(1%) MT consist of 50% of all tumours in bitch Malignant or benign 30% to 50% are malignant malignant tumours spread through
lymphatics and blood vessels primarily to regional lymph nodes and lungs
Other metastatic sites include adrenal glands, kidneys, heart and bones
20
/11
/20
10
![Page 3: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/3.jpg)
PATHOLOGICAL ASPECT
Benign tumours are usually fibroadenoma, adenomas or mesenchymal tumours
Most malignant tumours are carcinomas and these tend to spread after surgery
20
/11
/20
10
![Page 4: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/4.jpg)
ETIOLOGY
Unknown
Hormone dependent
Estrogen and progesterone seems to have a role
Estrogen and progesterone receptors are found in 50% malignant and 70% of benign canine MTs
20
/11
/20
10
![Page 5: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/5.jpg)
OHE AND MAMMARY TUMOUR
MT are prevented if OHE is done before 1 year of age
Risk of developing MT is only 0.05% in bitches spayed before 1st estrous
Risk increases to 8% and 26% after 1st and 2nd estrous respectively
No effect of OHE on MT after 2.5years
20
/11
/20
10
![Page 6: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/6.jpg)
CASE HISTORY
Case no. Date: 7/10/10Spp: canineBreed: labradorAge: 10 yearsSex: FemaleColour: fawnWeight: 27 kg
20
/11
/20
10
![Page 7: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/7.jpg)
HISTORY
Hard lump present on abdomen for last 2 months
Fast growing
Non pregnant and non lactating for last 2 years
Engorgement of teats before 6 month
20
/11
/20
10
![Page 8: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/8.jpg)
PHYSICAL FINDINGS
Tumour like growth of about 12cm diameter involving 2nd right teat
Ulcerated growth was firm but easily movable below the skin
All physiological parameters were found to be normal
Right axillary lymph nodes were palpable (slight swollen)
20
/11
/20
10
![Page 9: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/9.jpg)
DIAGNOSIS 20
/11
/20
10
• Based on history and visual observation
Mammary Tumour
![Page 10: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/10.jpg)
TREATMENT
Medicinal management Antiestrogens (tamoxifen @0.4 to 0.8mg/kg/d
PO), antiprogestins or antiprolactins are advocated by some.
Chemotherapy but no particular protocol. Adriamycin and cyclophosphamide combinations are used
Radiation therapy Immunotherapy Surgical excision is the treatment of choice So it was adopted with out any delay
20
/11
/20
10
![Page 11: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/11.jpg)
PREOPERATIVE MANAGEMENT
0.5mg/kg of Pheneramine maleate was given i/m
1ml of dexamethasone s/c
Carbazochrome salicylate 1ml i/m
20
/11
/20
10
![Page 12: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/12.jpg)
PRE ANESTHETICS
Triflupromazine HCL @ 1mg/kg body weight i/v
Atropine sulphate @0.04mg/kg body weight s/c
20
/11
/20
10
![Page 13: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/13.jpg)
PREPARATION OF SURGICAL SITE
Savlon was applied on the intended area and shaving was done liberally to prepare the site
20
/11
/20
10
![Page 14: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/14.jpg)
ANESTHESIA
Thiopentone Na @ 20mg/kg body weight i/v
5% solution was prepared and 1/3rd was sufficient for induction
2/3rd was used for maintenance
Total dose of 300mg was sufficient for the whole surgical procedure to complete successfully
20
/11
/20
10
![Page 15: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/15.jpg)
SURGICAL PROCEDURE 20
/11
/20
10
![Page 16: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/16.jpg)
POST-OPERATIVE THERAPY Antibiotics – ceftriaxone 500 mg i/m for 5
days
NSAID- meloxicam @ 0.5 mg/kg for 5 days
Antihistaminic- pheneramine maleate @ 0.5mg/kg for 4 more days
RL 200ml i/v for 2days
Daily dressing of surgical wound for 5 days.
20
/11
/20
10
![Page 17: Surgical management of mammary tumour in canines](https://reader034.vdocuments.site/reader034/viewer/2022042518/5480bc335906b5186d8b45a7/html5/thumbnails/17.jpg)
20
/11
/20
10